NautaDutilh assists Arvelle Therapeutics on acquiring exclusive rights to develop and commercialise anti-epileptic drug
NautaDutilh assisted Biotech company Axovant Sciences and newly created company Arvelle Therapeutics B.V. - alongside Cooley acting as US Counsel - on acquiring the exclusive rights from SK Biopharmaceuticals to develop and commercialise Cenobamate in Europe. Cenobamate was discovered by SK Biopharmaceuticals and is a novel investigational anti-epileptic drug for the potential treatment of focal seizures which is a form of an epileptic seizure. Arvelle will provide SK Biopharmaceuticals with an upfront payment of USD 100 million with a future milestone potential of up to USD 430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe.
Arvelle Therapeutics B.V. received one of the largest initial financing commitments for an European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners.
Amongst others, the NautaDutilh team consisted of Ruud Smits, Sybren de Beurs, Marieke Pols and Daan Hannema (Corporate M&A), Wijnand Bossenbroek and Daan Hagelstein (Corporate Notariaat), Antonia Netiv and Joppe Schoute (Capital Markets) and Michelle van Doren (Finance).
